124 related articles for article (PubMed ID: 37824367)
1. The Mutational and Transcriptional Landscapes of Speckle-Type POZ Protein (SPOP) and Androgen Receptor (AR) in a Single-Center pT3 Prostatectomy Cohort.
Eryilmaz IE; Vuruskan BA; Kaygisiz O; Cecener G; Egeli U; Vuruskan H
J Environ Pathol Toxicol Oncol; 2024; 43(1):15-29. PubMed ID: 37824367
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
3. G3BP1 inhibits Cul3
Mukhopadhyay C; Yang C; Xu L; Liu D; Wang Y; Huang D; Deonarine LD; Cyrta J; Davicioni E; Sboner A; Robinson BD; Chinnaiyan AM; Rubin MA; Barbieri CE; Zhou P
Nat Commun; 2021 Nov; 12(1):6662. PubMed ID: 34795264
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
5. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J; Wang C; Deng Y; Yu L; Huang H
Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
[TBL] [Abstract][Full Text] [Related]
6. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
[TBL] [Abstract][Full Text] [Related]
7. Speckle-type POZ protein mutations interrupt tumor suppressor function of speckle-type POZ protein in prostate cancer by affecting androgen receptor degradation.
Lai J; Batra J
Asian J Androl; 2014; 16(5):659-60. PubMed ID: 24969063
[TBL] [Abstract][Full Text] [Related]
8. Identification of speckle-type POZ protein somatic mutations in African American prostate cancer.
Buckles E; Qian C; Tadros A; Majumdar S; Cvitanovic J; Zabaleta J; Estrada J; Wilson J; Liu W
Asian J Androl; 2014; 16(6):829-32. PubMed ID: 24994784
[TBL] [Abstract][Full Text] [Related]
9. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
[TBL] [Abstract][Full Text] [Related]
10. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
[TBL] [Abstract][Full Text] [Related]
12. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
13. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the SPOP mutant genomic subclass in prostate cancer.
Shoag J; Liu D; Ma X; Oromendia C; Christos P; Ballman K; Angulo C; Cai PY; Gaffney C; Klein E; Karnes J; Den RB; Liu Y; Davicioni E; Barbieri CE
Urol Oncol; 2020 May; 38(5):418-422. PubMed ID: 32192889
[TBL] [Abstract][Full Text] [Related]
15. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
16. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
17. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
18. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
19. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
Fong KW; Zhao JC; Song B; Zheng B; Yu J
Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
[TBL] [Abstract][Full Text] [Related]
20. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.
Grbesa I; Augello MA; Liu D; McNally DR; Gaffney CD; Huang D; Lin K; Ivenitsky D; Goueli R; Robinson BD; Khani F; Deonarine LD; Blattner M; Elemento O; Davicioni E; Sboner A; Barbieri CE
Cell Rep; 2021 Sep; 36(10):109625. PubMed ID: 34496233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
